QVT Financial’s Cellectis CLLS Stock Holding History

QVT Financial’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-25,353	Closed	-$655K	–	73
2017 Q2	$655K	Buy	+25,353	New	+$605K	0.02%	69

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

QVT Financial's CLLS Position: Q3 2017 in Review

QVT Financial sold out of Cellectis (CLLS) in Q3 2017, closing a stake of 25,353 shares — an estimated $655K sold.

QVT Financial first reported a position in CLLS in Q2 2017 and held it in 1 quarter. The position peaked at $655K in Q2 2017. 42 funds tracked by Wall St. Rank hold CLLS as of Q3 2017.

QVT Financial reported no remaining Cellectis position as of Q3 2017 after selling out during the quarter.
QVT Financial sold 25,353 Cellectis shares in Q3 2017, an estimated $655K.
QVT Financial first reported a position in Cellectis in Q2 2017 and held it in 1 quarter.
QVT Financial's Cellectis position peaked at $655K in Q2 2017.
42 funds tracked by Wall St. Rank held Cellectis as of Q3 2017.

Based on QVT Financial's 13F filing for Q3 2017, filed 14 Nov 2017.